Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv
Mandate

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

January 14, 2026

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.

The purchase price amounted to USD 91 million. Furthermore, Orexo is entitled to a contingent consideration of up to USD 16.8 million, based on future Zubsolv net sales during 2026 and 2027. Steptoe LLP acted as lead legal counsel in connection with the transaction and Vinge advised Orexo in relation to Swedish law.

Vinge’s team consisted of Rikard Lindahl, Viveka Classon, Kim Bergman Aldevinge and Sara Stålebring.

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

 Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

 United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026